Under construction – not a live service
Sign in
Taking people in ArgentinaNo phase

Studies hereditary transthyretin amyloidosis with the Val50Met variant outside endemic areas

Describes how hereditary transthyretin amyloidosis with Val50Met appears in people 20 years or older.

Plain-language title generated from the registry record
Registry title: Phenotypic Manifestations of Hereditary ATTR Amyloidosis

Key facts

Where
Charata, ArgentinaSee the 2 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 20 to 70 who carry the Val50Met variant of hereditary transthyretin amyloidosis.

Age
20 to 70 years
Sex
All sexes can join.
Biomarker or test result
Carrier of the Val50Met variant.

Main reasons for not taking part

  • People who refuse to take part

Read by machine on 12 November 2026.

Where in Argentina

  • Hospital las Breñas 9 de JulioCharata, ArgentinaContact: Mauricio MT TOMEI, MDEnrolling by invitation
  • Hosptial Las BreñasCharata, ArgentinaContact: Mauricio MT TOMEI, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Hospital 9 de Julio de Las Breñas
Trial code
NCT07124377
Record updated
2 April 2026
Original description
This study focuses on hereditary transthyretin amyloidosis (ATTRv) with the Val50Met variant in a non endemic aereaRead full original descriptionShow less

Phenotypic Manifestations of Hereditary ATTR Amyloidosis Val50Met Variant in a Non-endemic Area. Descriptive Study

This study focuses on hereditary transthyretin amyloidosis (ATTRv) with the Val50Met variant in a non endemic aerea

Inclusion: All subjects between 20 and 70 years of age, carriers of the Val50Met variant.

Exclusion: Patients who refuse to participate.

ClinicalTrials.gov NCT07124377